ScholarIQanswers from OpenAlex & ORCID
Todd M. Bauer
ResearcherPublications, citations & collaboration network
Todd M. Bauer is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Todd M. Bauer have?
ScholarIQindexed works
Todd M. Bauer has 531 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Todd M. Bauer have?
ScholarIQcitation count
Todd M. Bauer has 17,297 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Todd M. Bauer?
ScholarIQh-index
Todd M. Bauer has an h-index of 63 in OpenAlex.
What is the i10-index of Todd M. Bauer?
ScholarIQi10-index
Todd M. Bauer has an i10-index of 187 in OpenAlex.
What is the ORCID of Todd M. Bauer?
ScholarIQorcid
The ORCID for Todd M. Bauer is on the source record.
What is the OpenAlex record for Todd M. Bauer?
ScholarIQopenalex
The OpenAlex for Todd M. Bauer is on the source record.
What are the most-cited papers on Todd M. Bauer?
ScholarIQmost cited works
First-Line Lorlatinib or Crizotinib in Advanced <i>ALK</i> -Positive Lung Cancer
Alice T. Shaw, Todd M. Bauer, Filippo de Marinis, Enriqueta Felip, Yasushi Goto, Geoffrey Liu, Julien Mazières, Dong‐Wan Kim, Tony Mok, Anna Polli, Holger Thurm, Anna Maria Calella, Gerson Peltz, Benjamin Solomon
Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)
Alexander Drilon, Salvatore Siena, Sai‐Hong Ignatius Ou, Manish R. Patel, Myung‐Ju Ahn, Jeeyun Lee, Todd M. Bauer, Anna F. Farago, Jennifer J. Wheler, Stephen V. Liu, Robert C. Doebele, Laura Giannetta, Giulio Cerea, Giovanna Marrapese, Michele Schirru, Alessio Amatu, Katia Bencardino, Laura Palmeri, Andrea Sartore‐Bianchi, Angelo Vanzulli, Sara Cresta, Silvia Damian, Matteo Duca, Elena Ardini, Gang Li, Jason Christiansen, Karey Kowalski, Ann Johnson, Rupal Patel, David Luo, Edna Chow‐Maneval, Zachary Hornby, Pratik S. Multani, Alice T. Shaw, Filippo de Braud
Activation of MET via Diverse Exon 14 Splicing Alterations Occurs in Multiple Tumor Types and Confers Clinical Sensitivity to MET Inhibitors
Garrett M. Frampton, Siraj M. Ali, Mark R. Rosenzweig, Juliann Chmielecki, Xinyuan Lu, Todd M. Bauer, Mikhail Akimov, José A. Bufill, Carrie B. Lee, David Jentz, Rick Hoover, Sai‐Hong Ignatius Ou, Ravi Salgia, Timothy J. Brennan, Zachary R. Chalmers, Savina Jaeger, Alan Huang, Julia A. Elvin, Rachel Erlich, Alex Fichtenholtz, Kyle Gowen, Joel Greenbowe, Adrienne Johnson, Depinder Khaira, Caitlin McMahon, Eric M. Sanford, Steven Roels, Jared White, Joel Greshock, Robert Schlegel, Doron Lipson, Roman Yelensky, Deborah Morosini, Jeffrey S. Ross, Eric A. Collisson, Malte Peters, Philip J. Stephens, Vincent A. Miller
Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study
Benjamin Solomon, Benjamin Besse, Todd M. Bauer, Enriqueta Felip, Ross A. Soo, D. Ross Camidge, Rita Chiari, Alessandra Bearz, Chia‐Chi Lin, Shirish M. Gadgeel, Gregory J. Riely, Eng Huat Tan, Takashi Seto, Leonard P. James, Jill S. Clancy, Antonello Abbattista, Jean-François Martini, Joseph Chen, Gerson Peltz, Holger Thurm, Sai‐Hong Ignatius Ou, Alice T. Shaw
Efficacy of Selpercatinib in <i>RET</i> -Altered Thyroid Cancers
Lori J. Wirth, Eric J. Sherman, Bruce Robinson, Benjamin Solomon, Hyunseok Kang, Jochen H. Lorch, Francis P. Worden, Marcia S. Brose, Jyoti D. Patel, Sophie Leboulleux, Yann Godbert, Fabrice Barlési, John C. Morris, Taofeek K. Owonikoko, Daniel S.W. Tan, Oliver Gautschi, Jared Weiss, Christelle de la Fouchardière, Mark E. Burkard, Janessa Laskin, Matthew H. Taylor, Matthias Kroiß, Jacques Médioni, Jonathan W. Goldman, Todd M. Bauer, Benjamin Levy, Viola W. Zhu, Nehal J. Lakhani, Víctor Moreno, Kevin Ebata, Michele Nguyen, Dana Heirich, Edward Y. Zhu, Xin Huang, Luxi Yang, Jennifer Kherani, S. Michael Rothenberg, Alexander Drilon, Vivek Subbiah, Manisha H. Shah, Maria E. Cabanillas